Evidence map›Paper›PMID 39580470›Full record

ArticleNature communications2024

Outcome of SARS-CoV-2 reinfection depends on genetic background in female mice.

Gagandeep Singh, Juan García-Bernalt Diego, Prajakta Warang, Seok-Chan Park, Lauren A Chang, Moataz Noureddine, Gabriel Laghlali, Yonina Bykov, Matthew Prellberg, Vivian Yan and 6 more

Abstract read
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Crosstalk betweenFrontiers in immunology · 2026
    Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Gagandeep Singh *Department of Microbiology, Icahn School of Medicine at Mount Sinai New York, New York, NY, USA.ORCID 0000-0003-3260-2631
Juan García-Bernalt Diego *Department of Microbiology, Icahn School of Medicine at Mount Sinai New York, New York, NY, USA.ORCID 0000-0001-6947-6806
Prajakta WarangDepartment of Microbiology, Icahn School of Medicine at Mount Sinai New York, New York, NY, USA.ORCID 0000-0002-5571-8277
Seok-Chan ParkDepartment of Microbiology, Icahn School of Medicine at Mount Sinai New York, New York, NY, USA.
Lauren A ChangDepartment of Microbiology, Icahn School of Medicine at Mount Sinai New York, New York, NY, USA.ORCID 0000-0002-3287-3987
Moataz NoureddineDepartment of Microbiology, Icahn School of Medicine at Mount Sinai New York, New York, NY, USA.
Gabriel LaghlaliDepartment of Microbiology, Icahn School of Medicine at Mount Sinai New York, New York, NY, USA.
Yonina BykovDepartment of Microbiology, Icahn School of Medicine at Mount Sinai New York, New York, NY, USA.
Matthew PrellbergDepartment of Microbiology, Icahn School of Medicine at Mount Sinai New York, New York, NY, USA.ORCID 0000-0001-9608-789X
Vivian YanDepartment of Microbiology, Icahn School of Medicine at Mount Sinai New York, New York, NY, USA.ORCID 0009-0009-0397-623X
Sarabjot SinghRT-PCR COVID-19 Laboratory, Civil Hospital, Moga, Punjab, India.
Lars PacheNCI Designated Cancer Center, Sanford-Burnham Prebys Medical Discovery Institute, 10901 N Torrey Pines Rd, La Jolla, CA, 92037, USA.ORCID 0000-0002-4193-1042
Sara Cuadrado-CastanoDepartment of Microbiology, Icahn School of Medicine at Mount Sinai New York, New York, NY, USA.ORCID 0000-0002-9400-746X
Brett WebbDepartment of Veterinary Sciences, University of Wyoming, Laramie, WY, USA.
Adolfo García-SastreDepartment of Microbiology, Icahn School of Medicine at Mount Sinai New York, New York, NY, USA.ORCID 0000-0002-6551-1827
Michael SchotsaertDepartment of Microbiology, Icahn School of Medicine at Mount Sinai New York, New York, NY, USA. michael.schotsaert@mssm.edu.ORCID 0000-0003-3156-3132

Funding

NIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities75N93021C00014 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI GARCIA-SASTRE, ADOLFO · 2021 to 2025
$62.6M
SARS-CoV adaptations through a Systems Biology Lens (SYBIL)U19AI135972 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Adolfo Garcia-Sastre · 2018 to 2026
$27.2M
TRAINING PROGRAM: MECHANISMS OF VIRUS-HOST INTERACTIONST32AI007647 · NIAID · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI Domenico Tortorella · 2000 to 2026
$11.5M
Supplement: Adjuvant Screening for an inactivated SFTSV Vaccine75N93019C00046 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI ADOLFO, GARCIA-SASTRE · 2019 to 2023
$9.1M
Combined adjuvant approaches for enhancement of SARS-CoV-2 vaccine efficacyR01AI160706 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SCHOTSAERT, MICHAEL, WONG, PAMELA TINMOI · 2022 to 2025
$2.9M
Experimental and natural SARS-CoV-2 infection of the human pancreasR01DK130425 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI HOMANN, DIRK, SCHOTSAERT, MICHAEL · 2021 to 2023
$1.3M
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (Division of Intramural Research of the NIAID) U19AI135972NIAID NIH HHS 75N93019C00046NIAID NIH HHS 75N93021C00014NIAID NIH HHS R01 AI160706NIAID NIH HHS T32 AI007647NIAID NIH HHS U19 AI135972NIDDK NIH HHS R01 DK130425U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R01AI160706U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (National Institute of Diabetes & Digestive & Kidney Diseases) R01DK130425
6 · The paper itself

Abstract

Antigenically distinct SARS-CoV-2 variants increase the reinfection risk for vaccinated and previously exposed population due to antibody neutralization escape. COVID-19 severity depends on many variables, including host immune responses, which differ depending on genetic predisposition. To address this, we perform immune profiling of female mice with different genetic backgrounds -transgenic K18-hACE2 and wild-type 129S1- infected with the severe B.1.351, 30 days after exposure to the milder BA.1 or severe H1N1. Prior BA.1 infection protects against B.1.351-induced morbidity in K18-hACE2 but aggravates disease in 129S1. H1N1 protects against B.1.351-induced morbidity only in 129S1. Enhanced severity in B.1.351 re-infected 129S1 is characterized by an increase of IL-10, IL-1β, IL-18 and IFN-γ, while in K18-hACE2 the cytokine profile resembles naïve mice undergoing their first viral infection. Enhanced pathology during 129S1 reinfection cannot be attributed to weaker adaptive immune responses to BA.1. Infection with BA.1 causes long-term differential remodeling and transcriptional changes in the bronchioalveolar CD11c+ compartment. K18-hACE2 CD11c+ cells show a strong antiviral defense expression profile whereas 129S1 CD11c+ cells present a more pro-inflammatory response upon restimulation. In conclusion, BA.1 induces cross-reactive adaptive immune responses in K18-hACE2 and 129S1, but reinfection outcome correlates with differential CD11c+ cells responses in the alveolar space.

Indexed as

COVID-19CytokinesReinfectionSARS-CoV-2Angiotensin-Converting Enzyme 2AnimalsDisease Models, AnimalFemaleGenetic BackgroundHumansInfluenza A Virus, H1N1 SubtypeLungMiceMice, TransgenicAngiotensin-Converting Enzyme 2Cytokines

Identifiers

PMID39580470
PMCPMC11585546

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.